In primary Sjögren's syndrome high absolute numbers and proportions of B cells in parotid glands predict responsiveness to rituximab as defined by ESSDAI, but not by SSRI
| Autor: | Rodney P. E. Pollard, Frans G. M. Kroese, Konstantina Delli, Arjan Vissink, Frederik Spijkervet, Hendrika Bootsma, Stephan Ihrler, Bert van der Vegt, Erlin A. Haacke |
|---|---|
| Přispěvatelé: | Translational Immunology Groningen (TRIGR), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Personalized Healthcare Technology (PHT), Guided Treatment in Optimal Selected Cancer Patients (GUTS) |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty T cell Immunology SALIVARY-GLANDS Inflammation DISEASE-ACTIVITY CONTROLLED-TRIAL General Biochemistry Genetics and Molecular Biology 03 medical and health sciences Antibodies Monoclonal Murine-Derived 0302 clinical medicine Rheumatology Internal medicine Parenchyma medicine Immunology and Allergy Humans Parotid Gland GeneralLiterature_REFERENCE(e.g. dictionaries encyclopedias glossaries) INDEX 030203 arthritis & rheumatology CD20 B-Lymphocytes Salivary gland biology business.industry EFFICACY Parotid gland 030104 developmental biology medicine.anatomical_structure Endocrinology Sjogren's Syndrome biology.protein ComputingMethodologies_DOCUMENTANDTEXTPROCESSING Histopathology Rituximab medicine.symptom business medicine.drug |
| Zdroj: | Annals of the Rheumatic Diseases, 75(6):e34. BMJ PUBLISHING GROUP |
| ISSN: | 1468-2060 0003-4967 |
| Popis: | With great interest we have read the letter to the editor by Cornec et al 1 regarding our paper ‘Towards personalised treatment in primary Sjogren's syndrome (pSS): baseline parotid histopathology predicts responsiveness to rituximab treatment’.2 In essence, we showed in our paper that absolute numbers of CD20+ cells/mm2 of parenchyma of parotid gland tissue are predictive for the responsiveness of patients with pSS to rituximab (RTX) treatment. Cornec et al argue that there is a discrepancy in outcomes presented in their study and our study,1 as they observed that a high proportion of minor salivary gland B cells predict the absence of a clinical response to RTX.3 As we will show and explain here, there is no inconsistency between the two studies and most of the apparent discrepancy is likely the result of differences in how the tissues are analysed and how the disease activity is established. A major difference in the two studies is how B cells are assessed in tissue sections of salivary gland biopsies of patients with pSS before (and after) RTX treatment. We measured absolute numbers of CD20+ B cells/mm2 of parenchyma, while Cornec et al assessed the proportion of B cells.1 ,3 Obviously, even when there is a change in absolute numbers of B cells in the tissue, the B/T cell ratio still can remain the same. Thus, although higher numbers of B cells, do not need to be reflected per se in higher proportions of B cells, we also found in our study that patients with higher absolute numbers of B cells in the glandular tissue, had a higher B/B+T cell ratio. Furthermore, responders to RTX, as defined by a decrease in European League Against … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|